This list shows candidate vaccines and their research stage on May 20th, 2020.
| Candidate vaccines in clinical evaluation: 9 | |||
| Vaccine | Platform | Developer/
Location |
Stage |
| Ad5-nCoV | Non-
Replicating Viral Vector |
CanSinoBiological Inc./ Beijing Institute of Biotechnology
(China) |
Phase II
Phase I |
| mRNA-1273 | RNA | Moderna/NIAID
(U.S.) |
Phase 2
(IND accepted) Phase 1 |
| ChAdOx1 nCoV-19 | Non- Replicating Viral Vector | University of Oxford
(UK) |
Phase I/II |
| – | Inactivated | Wuhan Institute of Biological Products/Sinopharm
(China) |
Phase I/II |
| – | Inactivated | Beijing Institute of Biological Products/Sinopharm | Phase 1/II |
| – | Inactivated | Sinovac Biotech Co.
(China) |
Phase I/II |
| BNT162 | RNA | BioNTech/Fosun Pharma/Pfizer
(Germany) |
Phase I/II |
| INO-4800 | DNA | Inovio Pharmaceuticals
(U.S.) |
Phase I |
| LV-SMENP | Lentiviral | Shenzhen Geno-immune Medical Institute | Phase I/II |
| Pathogen-specific aAPC | Lentiviral | Shenzhen Geno-Immune Medical Institute | Phase I |
| Candidates vaccines in preclinical evaluation : 109 | |||
| Protein Subunit | 41 | ||
| RNA | 14 | ||
| Replicating Viral Vector | 14 | ||
| Non-Replicating Viral Vector | 13 | ||
| DNA | 9 | ||
| VLP | 7 | ||
| Inactivated | 5 | ||
| Live Attenuated Virus | 3 | ||
| Unknown | 3 | ||
These data come from a document produced by the World Health Organization and an article by Nature.com identifying the current COVID-19 candidate vaccines. This document will be frequently updated by personal researches on clinicaltrials.gov.
Sources :
- Thanh Le T., Andreadakis Z., Kumar A., et al (April 9, 2020) The COVID-19 vaccine development landscape. Nature.com, Retrieved from https://www.nature.com/articles/d41573-020-00073-5
- U.S National Library of Medicine. https://clinicaltrials.gov/
- World Health Organization. (April 11, 2020) DRAFT landscape of COVID-19 candidate vaccines. Retrieved from https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/